乳腺导管原位癌的单中心预后分析

杨贻兰; 赵旭; 陈星星; 汪宣伊; 金恺睿; 章真; 邵志敏; 郭小毛; 俞晓立

doi:10.19401/j.cnki.1007-3639.2022.03.005

您当前的位置：

首页 >

文章列表页 >

乳腺导管原位癌的单中心预后分析

论著 | 更新时间：2025-12-31

- 乳腺导管原位癌的单中心预后分析
- A single-center prognotic analysis of breast ductal carcinoma in situ
- 中国癌症杂志 2022年32卷第3期页码：228-233
- 作者机构：
  
  1. 复旦大学附属肿瘤医院放射治疗中心,复旦大学上海医学院肿瘤学系,上海 200032
  2. 上海市放射肿瘤学重点实验室,上海 200032
  3. 复旦大学附属肿瘤医院乳腺外科,复旦大学上海医学院肿瘤学系,上海 200032
- 作者简介：
  
  俞晓立 E-mail: stephanieyxl@hotmail.com
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2022.03.005
  中图分类号： R737.9
- 收稿：2021-11-25，
  
  纸质出版：2022-03-30
- 稿件说明：
移动端阅览
杨贻兰, 赵旭, 陈星星, 等. 乳腺导管原位癌的单中心预后分析[J]. 中国癌症杂志, 2022,32(3):228-233.

Yilan YANG, Xu ZHAO, Xingxing CHEN, et al. A single-center prognotic analysis of breast ductal carcinoma in situ[J]. China Oncology, 2022, 32(3): 228-233.
杨贻兰, 赵旭, 陈星星, 等. 乳腺导管原位癌的单中心预后分析[J]. 中国癌症杂志, 2022,32(3):228-233. DOI： 10.19401/j.cnki.1007-3639.2022.03.005.

Yilan YANG, Xu ZHAO, Xingxing CHEN, et al. A single-center prognotic analysis of breast ductal carcinoma in situ[J]. China Oncology, 2022, 32(3): 228-233. DOI： 10.19401/j.cnki.1007-3639.2022.03.005.

摘要

背景与目的：

目前中国乳腺导管原位癌（ductal carcinoma

in situ

DCIS）的发病率逐年升高

而现有治疗策略主要基于欧美大型随机对照研究。探索中国人群中DCIS患者的临床特征、复发模式和预后影响因素

以便优化临床决策。

方法：

回顾性分析2008年1月

#x02014;2017年1月复旦大学附属肿瘤医院收治的1 185例DCIS患者的病历资料

采用Kaplan-Meier法计算无局部复发生存（local recurrence-free survival

LRFS）率、无病生存（disease-free survival

DFS）率和总生存（overall survival

OS）率

采用COX风险比例回归模型进行单因素和多因素分析。

结果：

中位随访时间为61个月

5年OS率、LRFS率和DFS率分别为99.9%、98.7%和96.6%。随访期间共观察到50例治疗失败事件

包括局部区域复发16例、对侧乳腺事件30例和远处转移4例。多因素分析中

人表皮生长因子受体2（human epidermal growth factor receptor 2

HER2）阳性的患者更容易发生局部区域复发

LRFS率较差（

=0.029）。

结论：

DCIS患者预后极好

HER2阳性是LRFS的不良预后因素。

Abstract

Background and purpose:

The incidence of ductal carcinoma

in situ

(DCIS) has increased annually with the popularity of mammography screening. However

current treatment strategies are mostly based on the results of prospective randomized clinical trials in western countries. This study aimed to explore the clinical characteristics

recurrence patterns and prognostic factors of Chinese DCIS patients

hoping to optimize clinical decision-making.

Methods:

Medical records of 1 185 DCIS patients treated in Fudan University Shanghai Cancer Center from January 2008 to January 2017 were retrospectively analyzed. The local recurrence-free survival (LRFS) rate

disease-free survival (DFS) rate and overall survival (OS) rate were

calculated using the Kaplan-Meier method. Univariate and multivariate analyses were performed using the COX proportional hazards regression model.

Results:

With a median follow-up of 61 months

50 treatment failure events were observed

including 16 locoregional recurrences

30 contralateral breast cancer events and 4 distant metastases. The 5-year OS rate

LRFS rate and DFS rate were 99.9%

98.7% and 96.6%

respectively. In the multivariate analysis

the positive status of human epidermal growth factor receptor 2 (HER2) was related to higher risk of local recurrence and the LRFS rate was poor (

=0.029).

Conclusion:

The patient with DCIS was associated with favorable prognosis. HER2 positivity was the risk factor for poor LRFS.

关键词

Keywords

references

WARD E M , DESANTIS C E , LIN C C , et al . Cancer statistics: breast cancer in situ [J ] . CA Cancer J Clin , 2015 , 65 ( 6 ): 481 - 495 . DOI: 10.3322/caac.21321 http://doi.org/10.3322/caac.21321 http://doi.wiley.com/10.3322/caac.21321 http://doi.wiley.com/10.3322/caac.21321

LI C Y , YANG Y L , WANG J F , et al . Characteristics, prognosis, risk factors, and management of recently diagnosed ductal carcinoma in situ with microinvasion [J ] . Cancer Med , 2021 , 10 ( 20 ): 7203 - 7212 . DOI: 10.1002/cam4.v10.20 http://doi.org/10.1002/cam4.v10.20 https://onlinelibrary.wiley.com/toc/20457634/10/20 https://onlinelibrary.wiley.com/toc/20457634/10/20

SIEGEL R L , MILLER K D , FUCHS H E , et al . Cancer statistics, 2021 [J ] . CA Cancer J Clin , 2021 , 71 ( 1 ): 7 - 33 . DOI: 10.3322/caac.v71.1 http://doi.org/10.3322/caac.v71.1 https://onlinelibrary.wiley.com/toc/15424863/71/1 https://onlinelibrary.wiley.com/toc/15424863/71/1

BAXTER N N , VIRNIG B A , DURHAM S B , et al . Trends in the treatment of ductal carcinoma in situ of the breast [J ] . J Natl Cancer Inst , 2004 , 96 ( 6 ): 443 - 448 . DOI: 10.1093/jnci/djh069 http://doi.org/10.1093/jnci/djh069 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djh069 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djh069

WAPNIR I L , DIGNAM J J , FISHER B , et al . Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS [J ] . J Natl Cancer Inst , 2011 , 103 ( 6 ): 478 - 488 . DOI: 10.1093/jnci/djr027 http://doi.org/10.1093/jnci/djr027 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djr027 https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djr027

DONKER M , LITIÈRE S , WERUTSKY G , et al . Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ : 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase & #x02162; trial [J ] . J Clin Oncol , 2013 , 31 ( 32 ): 4054 - 4059 . DOI: 10.1200/JCO.2013.49.5077 http://doi.org/10.1200/JCO.2013.49.5077 http://ascopubs.org/doi/10.1200/JCO.2013.49.5077 http://ascopubs.org/doi/10.1200/JCO.2013.49.5077

CUZICK J , SESTAK I , PINDER S E , et al . Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ : long-term results from the UK/ANZ DCIS trial [J ] . Lancet Oncol , 2011 , 12 ( 1 ): 21 - 29 . DOI: 10.1016/S1470-2045(10)70266-7 http://doi.org/10.1016/S1470-2045(10)70266-7 https://linkinghub.elsevier.com/retrieve/pii/S1470204510702667 https://linkinghub.elsevier.com/retrieve/pii/S1470204510702667

MCCORMICK B , WINTER K , HUDIS C , et al . RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation [J ] . J Clin Oncol , 2015 , 33 ( 7 ): 709 - 715 . DOI: 10.1200/JCO.2014.57.9029 http://doi.org/10.1200/JCO.2014.57.9029 https://ascopubs.org/doi/10.1200/JCO.2014.57.9029 https://ascopubs.org/doi/10.1200/JCO.2014.57.9029

WÄRNBERG F , GARMO H , EMDIN S , et al . Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ : 20 years follow-up in the randomized SweDCIS Trial [J ] . J Clin Oncol , 2014 , 32 ( 32 ): 3613 - 3618 . DOI: 10.1200/JCO.2014.56.2595 http://doi.org/10.1200/JCO.2014.56.2595 http://ascopubs.org/doi/10.1200/JCO.2014.56.2595 http://ascopubs.org/doi/10.1200/JCO.2014.56.2595

ALLRED D C , ANDERSON S J , PAIK S , et al . Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ : a study based on NSABP protocol B-24 [J ] . J Clin Oncol , 2012 , 30 ( 12 ): 1268 - 1273 . DO I: 10.1200/JCO.2010.34.0141 http://doi.org/10.1200/JCO.2010.34.0141 http://ascopubs.org/doi/10.1200/JCO.2010.34.0141 http://ascopubs.org/doi/10.1200/JCO.2010.34.0141

COBLEIGH M A , ANDERSON S J , SIZIOPIKOU K P , et al . Comparison of radiation with or without concurrent trastuzumab for HER2-positive ductal carcinoma in situ resected by lumpectomy: a phase & #x02162; clinical trial [J ] . J Clin Oncol , 2021 , 39 ( 21 ): 2367 - 2374 . DOI: 10.1200/JCO.20.02824 http://doi.org/10.1200/JCO.20.02824 https://ascopubs.org/doi/10.1200/JCO.20.02824 https://ascopubs.org/doi/10.1200/JCO.20.02824

GOLDHIRSCH A , WINER E P , COATES A S , et al . Personalizing the treatment of women with early breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 [J ] . Ann Oncol , 2013 , 24 ( 9 ): 2206 - 2223 . DOI: 10.1093/annonc/mdt303 http://doi.org/10.1093/annonc/mdt303 https://linkinghub.elsevier.com/retrieve/pii/S0923753419369649 https://linkinghub.elsevier.com/retrieve/pii/S0923753419369649

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), CORREA C, MCGALE P, et al . Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast [J ] . J Natl Cancer Inst Monogr , 2010 , 2010 ( 41 ): 162 - 177 .

THORAT M A , LEVEY P M , JONES J L , et al . Prognostic and predictive value of HER2 expression in ductal carcinoma in situ : results from the UK/ANZ DCIS randomized trial [J ] . Clin Cancer Res , 2021 . [Online ahead of print ]

HAN K , NOFECH-MOZES S , NAROD S , et al . Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence [J ] . Clin Oncol (R Coll Radiol) , 2012 , 24 ( 3 ): 183 - 189 . DOI: 10.1016/j.clon.2011.09.008 http://doi.org/10.1016/j.clon.2011.09.008 https://linkinghub.elsevier.com/retrieve/pii/S0936655511008387 https://linkinghub.elsevier.com/retrieve/pii/S0936655511008387

DI CESARE P , PAVESI L , VILLANI L , et al . The relationships between HER2 overexpression and DCIS characteristics [J ] . Breast J , 2017 , 23 ( 3 ): 307 - 314 . DOI: 10.1111/tbj.12735 http://doi.org/10.1111/tbj.12735 https://onlinelibrary.wiley.com/doi/10.1111/tbj.12735 https://onlinelibrary.wiley.com/doi/10.1111/tbj.12735

浏览量

1165

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

时空转录组解析乳腺癌淋巴结转移与免疫调控相关性的进展及展望

SMARCA4缺失型肺恶性肿瘤的临床病理学特征及患者预后分析

87例唾液腺导管癌患者的治疗策略与预后分析：一项回顾性队列研究

放射性淋巴细胞减少对局限期小细胞肺癌患者预后的影响：一项队列研究

肢端型黑色素瘤组织中MITF的表达及其与临床、病理学特征及预后的相关性研究